The unit that ran the gene therapy trial during which 18-year-old Jesse
Gelsinger died last year will no longer carry out clinical studies. The
University of Pennsylvania in Philadelphia announced last week that its
Institute for Human Gene Therapy, directed by James Wilson, will now concentrate
on basic research. The decision comes as a serious blow to an institute that
once led the world in moving gene therapy from the lab to the clinic. Wilson
said in a statement that the institute would develop “a foundation of science
necessary to assure the ultimate success of this field.”
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Environment
Can cloud seeding save us from water bankruptcy?
Features
Environment
Carbon credits are flawed, but they can still help save forests
Analysis
ÎçÒ¹¸£Àû1000¼¯ºÏ
PCOS has been officially renamed PMOS, and it’s a momentous move
Comment
Physics
Why do particle physicists like spending time in fields?
Comment
Popular articles
Trending New Scientist articles
1
PCOS has been officially renamed PMOS, and it’s a momentous move
2
Where did the laws of physics come from? I think I've found the answer
3
PCOS postpones perimenopause and allows pregnancies at older ages
4
Huge study of ancient British DNA reveals only minor Roman influence
5
A lost ancient script reveals how writing as we know it really began
6
There has been a sudden increase in the rate of sea level rise
7
Red-light therapy does have health benefits but not the ones you think
8
Carbon credits are flawed, but they can still help save forests
9
Thought-provoking photographs capture what it feels like to have ADHD
10
Can cloud seeding save us from water bankruptcy?
